Belvedere Trading’s Capricor Therapeutics CAPR Stock Holding History

Belvedere Trading’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,053	Closed	-$38.5K	–	688
2023 Q2	$38.5K	Buy	+8,053	New	+$35.4K	﹤0.01%	574

Other funds holding CAPR

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Belvedere Trading's CAPR Position: Q3 2023 in Review

Belvedere Trading sold out of Capricor Therapeutics (CAPR) in Q3 2023, closing a stake of 8,053 shares — an estimated $38.5K sold.

Belvedere Trading first reported a position in CAPR in Q2 2023 and held it in 1 quarter. The position peaked at $38.5K in Q2 2023. 34 funds tracked by Wall St. Rank hold CAPR as of Q3 2023.

Belvedere Trading reported no remaining Capricor Therapeutics position as of Q3 2023 after selling out during the quarter.
Belvedere Trading sold 8,053 Capricor Therapeutics shares in Q3 2023, an estimated $38.5K.
Belvedere Trading first reported a position in Capricor Therapeutics in Q2 2023 and held it in 1 quarter.
Belvedere Trading's Capricor Therapeutics position peaked at $38.5K in Q2 2023.
34 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2023.

Based on Belvedere Trading's 13F filing for Q3 2023, filed 27 Oct 2023.